 |
Return Create A Forum - Home |
 |
--------------------------------------------------------- |
|
MS Speaks |
 |
https://msspeaks.createaforum.com |
|
--------------------------------------------------------- |
|
***************************************************** |
|
Return to: BRIUMVI (ublituximab) |
|
***************************************************** |
|
#Post#: 4920-------------------------------------------------- |
|
Briumvi sales doing well |
|
By: agate Date: September 7, 2025, 1:17 am |
|
--------------------------------------------------------- |
|
This board doesn't usually feature financial reports but it may |
|
be of interest that: |
|
[font=Arial][/font][quote][font=Arial][/font] |
|
[font=Arial][/size][TG Therapeutics'] primary revenue driver, |
|
BRIUMVI, is rapidly establishing itself as a commercial success |
|
story. TG Therapeutics reported total second-quarter 2025 |
|
revenue of $141.1 million, with U.S. sales of BRIUMVI |
|
contributing $138.8 million to this figure. This represents a |
|
substantial 91 percent year-over-year increase, highlighting the |
|
therapy's accelerating market adoption for multiple sclerosis |
|
treatment.[/font] |
|
[font=Arial][/size][/font] |
|
[font=Arial][/size]In response to this powerful sales |
|
trajectory, management has significantly raised its full-year |
|
2025 guidance. Instead of previous projections, TG Therapeutics |
|
now anticipates approximately $570 to $575 million in U.S. |
|
BRIUMVI revenue alone�a strong indicator of continued robust |
|
demand.[/font] |
|
[font=Arial][/size][/font][/quote][font=Arial][/font] |
|
ktiencheck.de/news/Artikel-TG_Therapeutics_Stock_Riding_a_Wave_o |
|
f_Commercial_Success-18985749 |
|
https://msspeaks.createaforum.com/ktiencheck.de/news/Artikel-TG_Therapeutics_St… |
|
***************************************************** |
